4.7 Article

18F-FDG PET/CT is useful for determining survival outcomes of patients with multiple myeloma classified as stage II and III with the Revised International Staging System

Related references

Note: Only part of the references are listed.
Review Oncology

Genomic complexity of multiple myeloma and its clinical implications

Salomon Manier et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2017)

Review Oncology

Evolutionary biology of high-risk multiple myeloma

Charlotte Pawlyn et al.

NATURE REVIEWS CANCER (2017)

Article Radiology, Nuclear Medicine & Medical Imaging

Image interpretation criteria for FDG PET/CT in multiple myeloma: a new proposal from an Italian expert panel. IMPeTUs (Italian Myeloma criteria for PET USe)

Cristina Nanni et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2016)

Article Radiology, Nuclear Medicine & Medical Imaging

FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0

Ronald Boellaard et al.

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2015)

Review Medicine, Research & Experimental

18F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders

Franco Dammacco et al.

CLINICAL AND EXPERIMENTAL MEDICINE (2015)

Review Radiology, Nuclear Medicine & Medical Imaging

State of the art imaging of multiple myeloma: Comparative review of FDG PET/CT imaging in various clinical settings

Charles Mesguich et al.

EUROPEAN JOURNAL OF RADIOLOGY (2014)

Article Hematology

Clonal competition with alternating dominance in multiple myeloma

Jonathan J. Keats et al.

BLOOD (2012)

Article Radiology, Nuclear Medicine & Medical Imaging

Metabolic Tumor Volume Assessed by 18F-FDG PET/CT for the Prediction of Outcome in Patients with Multiple Myeloma

Rosa Fonti et al.

JOURNAL OF NUCLEAR MEDICINE (2012)

Review Hematology

Multiple myeloma

Robert A. Kyle et al.

BLOOD (2008)